Compare Abbott Laboratories (ABT) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.9 (market cap $1.54B). The key difference: Abbott Laboratories is far larger — about 108.4× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | AMC | |
|---|---|---|
Market Cap | $166.94B | $1.54B |
Sector | Health | Media |
52-Week High | $136.62 | $3.54 |
52-Week Low | $82.57 | $0.95 |
Enterprise Value | $193.69B | $9.13B |
Dividend Yield | 2.63% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
AMC trades at $1.72, down 8.99% in the last session amid dilution concerns from recent equity offerings. The stock shows bearish technical signals with negative cash flows and a net loss of $632.4M in 2025. Recent news highlights summer box office strength but ongoing investor worries about share dilution and profitability. The company's debt remains high at $4.01B, though revenue reached $4.85B in 2025.
Outlook remains challenged by persistent losses and high leverage, though diversification into live events offers growth potential. Key risks include dilution from equity sales and weak cash generation. Analyst consensus is mixed with a $1.85 price target, suggesting limited upside from current levels amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
